NCT04685265View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

November 7, 2022

Study Completion Date

December 22, 2022

Conditions
Parkinson Disease
Interventions
DRUG

anle138b

capsule containing excipient and anle138b

DRUG

Placebo

matching placebo capsule containing excipient

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors

Collaborators (1)

Aptuit
All Listed Sponsors
collaborator

Aptuit

INDUSTRY

collaborator

Quotient Sciences

INDUSTRY

collaborator

Nottingham University Hospitals NHS Trust

OTHER

lead

MODAG GmbH

INDUSTRY

NCT04685265 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease | Biotech Hunter | Biotech Hunter